Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18144773 | 0.92 | HRH3 (0.58) | HRH3CYP2D6KCNH2 | |
| SCHEMBL18148313 | 0.86 | HRH3 (0.47) | HRH3CYP2D6KCNH2 | |
| SCHEMBL18153948 | 0.78 | HRH3 (0.57) | HRH3CYP2D6KCNH2 | |
| SCHEMBL18144953 | 0.77 | HRH3 (0.54) | HRH3CYP2D6KCNH2 | |
| SCHEMBL18144749 | 0.77 | HRH3 (0.53) | HRH3CYP2D6KCNH2 | |
| SCHEMBL18148508 | 0.77 | OPRD1 (0.45) | KCNH2 | |
| SCHEMBL18148283 | 0.77 | POLB (0.52) | CYP2D6 | |
| SCHEMBL18148336 | 0.77 | OPRD1 (0.45) | HRH3OPRL1 | |
| SCHEMBL18144830 | 0.76 | HRH3 (0.52) | HRH3CYP2D6KCNH2 | |
| SCHEMBL11918549 | 0.75 | HRH3 (0.53) | HRH3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637453-B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637453-B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637453-B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2016168598-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168598-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC6 | HRH3 1040/4885CYP2D6 3041/4885KCNH2 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.